REG - Montagu Pvt Eqty LLP Adv Medical Solutns. - Rule 2.8 Announcement

Advanced Medical SolutionsAnnouncement

24/04/2025 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX1063Ga&default-theme=true

RNS Number : 1063G  Montagu Private Equity LLP  24 April 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS
AND MERGERS (THE "CODE").

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

24 April 2025

 

Statement of Intention Not to Make an Offer for Advanced Medical Solutions
Group plc

Further to the announcements made on 27 March 2025 by Advanced Medical
Solutions Group plc (the "Company" or "AMS") and Montagu Private Equity LLP,
in its capacity as adviser to funds managed and/or advised by it or its
affiliates ("Montagu"), in relation to a possible offer, Montagu now confirms
that it does not intend to make an offer for AMS. As a result, Montagu and any
person(s) acting in concert with it will, except with the consent of the
Takeover Panel, be bound by the restrictions contained in Rule 2.8 of the
Code.

 

Under Note 2 on Rule 2.8 of the Code, Montagu, and any person(s) acting in
concert with it, reserves the right to set the restrictions in Rule 2.8 of the
Code aside in the following circumstances:

 

a)            with the agreement of the board of directors of AMS;

b)            following the announcement by or on behalf of a third
party of a firm intention to make an offer for AMS;

c)             if AMS announces a Rule 9 waiver proposal (as
described in Note 1 of the Notes on Dispensations from Rule 9 of the Code) or
a reverse takeover (as defined in the Code); and

d)            if there has been a material change of circumstances
(as determined by the Takeover Panel)

 

 

Enquiries:

 

 Greenbrook Advisory (PR Adviser to Montagu)                     +44 (0) 20 7952 2000
 James Madsen                                                    Montagu@greenbrookadvisory.com

 Jefferies International Limited (Financial Adviser to Montagu)  +44 (0) 20 7029 8000
 Philip Noblet
 Thomas Bective
 Jee Lee
 Eleanor McDonald

 

Important notices:

This announcement is not intended to and does not constitute an offer to buy
or the solicitation of an offer to subscribe for, sell or otherwise dispose
of, or an invitation to purchase or subscribe for any securities or the
solicitation of any vote in any jurisdiction whether pursuant to this
announcement or otherwise.

 

A copy of this announcement will be made available at Montagu's website on
https://montagu.com/news/ (https://montagu.com/news/) by no later than 12 noon
(London time) on 25 April 2024. For the avoidance of doubt, the contents of
this website are not incorporated into and do not form part of this
announcement.

The release, publication or distribution of this announcement in whole or in
part, directly or indirectly, in, into or from jurisdictions outside the
United Kingdom may be restricted by law and therefore persons in such
jurisdictions or into whose possession this announcement comes should inform
themselves about and observe such restrictions. Any failure to comply with the
restrictions may constitute a violation of the securities law of any such
jurisdiction.

 

This announcement has been prepared in accordance with English law and
information disclosed may not be the same as that which would have been
prepared in accordance with the laws of jurisdictions outside England.

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  OUPUSRSRVAUSUAR